Brandon Levy is a Health Communications Specialist for the NIH’s Intramural Research Program, where he works to increase the IRP’s public profile and ensure IRP scientists get the recognition they deserve. He particularly enjoys writing about the cutting-edge research performed at NIH but also produces videos and content for social media. Before joining the IRP, he worked as a science writer in NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and as a postbaccalaureate Intramural Research Training Award (IRTA) fellow in NIH’s National Institute of Mental Health (NIMH), spending his days putting people inside giant magnets and sending magnetic waves into their brains to shed light on the mysteries of learning and memory. When he’s not hunched over a computer keyboard, Brandon enjoys singing in his acapella group, reading, honing his skills as an amateur chef, and over-obsessing about college basketball.
Alternative to CRISPR/Cas9 May Cause Fewer Undesired Changes
IRP researchers have always worked on the cutting edge of biomedical science, from testing the first successful treatment for childhood schizophrenia to pioneering the first screening technique for HIV. In a new study, an IRP team recently achieved yet another first: simultaneously editing two genetic sites in mice using a brand-new approach called base editing that may prove to be more precise – and therefore safer – than other gene editing methods.
The NIH’s main campus in Bethesda, Maryland, may have the look and feel of a university campus, but the world-renowned research institution does not grant credentials like an M.D. or Ph.D. Instead, the Graduate Partnerships Program offers graduate students from schools around the world the opportunity to complete research for their Ph.D. dissertations in IRP labs while pursuing advanced degrees from their ‘host’ institutions.
Delivery Method Could Eventually Help Correct Mutations That Cause Hearing Loss
Most people probably think of viruses as villains that bring illnesses like measles, HIV, and the flu, but some viruses are proving to be valuable allies in the fight against genetic diseases. In a new study, a team of scientists from the NIH IRP and their colleagues showed the promise of a lab-designed virus for delivering gene therapies aimed at correcting hereditary hearing loss.
Potential biomarker may contribute to personalized treatments
Until recently, medical treatment has largely been one-size-fits-all, with doctors unable to separate patients into distinct groups that might benefit more or less from a particular approach. However, researchers are increasingly finding that individuals with the same disease can differ markedly in ways that might one day influence their care. A recent IRP study has identified a particular molecule that may have just such an impact for patients with damaged lungs.
Virtually all parents would agree that having kids is a massive undertaking, and not just after they’re born. Many couples struggle to conceive, and each year thousands of American women experience complications when giving birth. With the help of the NIH’s state-of-the-art supercomputer, Biowulf, IRP senior investigator Rajeshwari Sundaram, Ph.D., develops and refines statistical tools that can guide prospective parents and their doctors through these challenges.
While many people think staving off aging means drinking seaweed smoothies and swallowing fish oil supplements, the key to extending life increasingly appears to be not putting things in our mouths. In yet another example of the anti-aging powers of eating less — what scientists call caloric restriction — IRP researchers have identified the specific aging-induced cellular and molecular changes in arteries that are curbed by substantially reducing calorie intake.
For Americans and others living outside the tropics, a mosquito bite is nothing more than an itchy inconvenience, but for billions of others, it can lead to a life-or-death battle with malaria. In some cases, the illness can wreak havoc on the brain. A new IRP study has used magnetic resonance imaging (MRI) technology to demonstrate that an investigational therapy can reverse that damage in mice.
Science is a process of trial and error. Most successful research publications are preceded by at least a few false starts and perhaps weeks or even months of tinkering to get experiments to work. For IRP senior investigator Carson Chow, Ph.D., this process of testing and throwing out one potential solution after another is an essential part of his research, so much so that he may go through thousands of iterations before arriving at one that works. However, rather than test each approach himself, he leverages the IRP’s considerable computing power to considerably accelerate the process of sorting the wheat from the chaff.
The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract.
The human genome comprises roughly three billion base pairs and around 20,000 protein-coding genes, according to recent estimates. That’s a lot of information crammed into the tiny nucleus of a cell, and it doesn’t even include the many genes that do not produce a protein or the fact that most genes come in multiple flavors that vary in different individuals. Add to that the phenomenon of an identical gene being either more or less active in two different people and you can quickly end up with genomic datasets that would overload nearly any computer. Fortunately for IRP senior investigator Daniel Levy, M.D., the NIH IRP has one of the few computer systems in the world that can handle this mountain of information.
This page was last updated on Wednesday, March 15, 2023
